In the same line, progression-free survival was significantly shorter in tumours displaying high levels of ALCAM in comparison with medium- and low-expressing tumours (median progression-free survival times of 7, 8 and 17 months for high, medium and low expression, respectively, P=0.008, Table 3). Here, ALCAM is linked to neoplasm.